Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/13483
Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?
Front. Immunol. 2021 Apr 23;12:657144.
During the last decade, many studies have demonstrated the role of CMV specific T-cell immune response on controlling CMV replication and dissemination. In fact, it is well established that transplanted patients lacking CMV-specific T-cell immunity have an increased occurrence of CMV replication episodes and CMV-related complications. In this context, the use of adoptive transfer of CMV-specific T-cells has been widely investigated and applied to Hematopoietic Stem Cell Transplant patients and may be useful as a therapeutic alternative, to reconstitute the CMV specific T-cell response and to control CMV viremia in patients receiving a transplantation. However, only few authors have explored the use of T-cell adoptive transfer in SOT recipients. We propose a novel review in which we provide an overview of the impact of using CMV-specific T-cell adoptive transfer on the control of CMV infection in SOT recipients, the different approaches to stimulate, isolate and expand CMV-specific T-cells developed over the years and a discussion of the possible use of CMV adoptive cellular therapy in this SOT population. Given the timeliness and importance of this topic, we believe that such an analysis will provide important insights into CMV infection and its treatment/prevention.
CMV treatment | CMV-specific immune response | T-cell adoptive transfer | Cellular therapy | Cytomegalovirus
Adoptive Transfer | Cytokines | Cytomegalovirus | Cytomegalovirus Infections | Disease Management | Disease Susceptibility | Humans | Immunotherapy, Adoptive | Organ Transplantation | T-Cell Antigen Receptor Specificity | T-Lymphocytes | Treatment Outcome
Files in this item